Dystonia treatment: Patterns of medication use in an international cohort. (7th February 2017)

• Record Type: Journal Article
• Authors: Pirio Richardson, Sarah; Wegele, Ashley R.; Skipper, Betty; Deligtisch, Amanda; Jinnah, H.A.
• Is Part Of: Neurology. Volume 88:Number 6(2017)
• Page Start: 543
• Page End: 550
• Publication Date: 2017-02-07
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000003596
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To determine the frequency of medication use in patients with dystonia enrolled in an international biorepository study. Methods: In a cross-sectional analysis, we included 2, 026 participants enrolled at 37 sites in the United States, Canada, Europe, and Australia through Project 1 of the Dystonia Coalition, an international biorepository study. The primary aim was to assess the frequency of medication classes recommended for treating patients with dystonia, and the secondary aim was to compare characteristics (disease type, age, sex, duration of disease, comorbid conditions, severity). Results: Querying the database for the presence of any medication for dystonia used (includes both injectable and oral therapy), we found 73% using medications (n = 1, 488) and 27% using no dystonia medications (n = 538). Furthermore, 61% of the total sample used botulinum toxin (BoNT) therapy alone or in combination. Differences were found in medication use patterns by dystonia type, with the lowest oral medication use in focal dystonia and highest use in generalized dystonia; by region, with highest BoNT therapy rate reported in Italy and the lowest in the Northeast region of the United States; and by focal dystonia subtype, with highest BoNT therapy alone in blepharospasm and spasmodic dysphonia (49%) and lowest in other cranial dystonia (32%). Conclusions: The majority of patients with dystonia enrolled in the Dystonia Coalition Project 1 were using medications to treat their dystonia. Overall, a complex picture of medication use patterns emerged, with factors such as region, disease duration, type of dystonia, disease severity, and psychiatric comorbidities all playing a significant role.